Biohaven Is Maintained at Overweight by JP Morgan
Biohaven Analyst Ratings
J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating, Announces Target Price $68
Strong Buy Rating for Biohaven Ltd. on Troriluzole's Market Potential and Robust Pipeline
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $55
TD Cowen Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $64
Jefferies Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $64
Biohaven Is Maintained at Outperform by Bernstein
B of A Securities Maintains Buy on Biohaven, Raises Price Target to $62
BofA Securities Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $62
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $58 to $76
Buy Rating for Biohaven's Troriluzole Backed by Long-Term Efficacy Data and Positive Regulatory Outlook
Biohaven Price Target Maintained With a $59.00/Share by HC Wainwright & Co.
Buy Rating Affirmed for Biohaven Ltd. on Promising Troriluzole SCA Program Data and Potential Market Dominance
RBC Capital Remains a Buy on Biohaven Ltd. (BHVN)
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Kodiak Sciences (KOD)
Biohaven Is Maintained at Overweight by Piper Sandler
Biohaven Analyst Ratings